Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA) announced that CEO Arun Swaminathan and Dr. Stanley H. Appel will participate in a BTIG-hosted KOL webcast titled "Is Alzheimer's next for GLP-1s and Combos?" on February 27, 2025. The discussion, moderated by Juliette Lafille of BTIG, will explore the potential of GLP-1 agonists and combination therapies for treating Alzheimer's disease.
Key topics will include:
- Potential for GLP-1s to slow cognitive decline in Alzheimer's
- Effects on brain metabolism and neuroinflammation reduction
- Efficacy through combinations
- Future development pathways
Coya recently expanded its pipeline with COYA 303, an investigational biologic combining COYA 301 (proprietary low-dose interleukin-2) with a GLP-1 receptor agonist designed for subcutaneous administration to treat inflammatory diseases.
Coya Therapeutics (NASDAQ: COYA) reported positive results from a Phase 2 study of low-dose IL-2 (LD IL-2) in Alzheimer's disease patients. The 21-week, double-blind, placebo-controlled trial demonstrated statistically significant improvements in inflammatory blood markers with monthly dosing.
Key findings include reduced levels of proinflammatory markers CCL2 (p0.05) and IL-15 (p<0.001), increased anti-inflammatory cytokine IL-4 (p<0.01), and improved beta amyloid 42 clearance. Patients receiving monthly LD IL-2 showed a 4.93-point improvement in ADAS-Cog score compared to placebo.The study involved 38 participants aged 50-86 with Alzheimer's disease. Monthly dosing proved more effective than biweekly administration. The treatment was well-tolerated with no serious adverse events reported. The comprehensive data set will be presented throughout 2025.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The conference will be held virtually from February 11-12, 2025. CEO Arun Swaminathan, Ph.D., will deliver a presentation on Tuesday, February 11, 2025, from 10:00 to 10:30 AM ET in Track 3. The presentation will be accessible via webcast, with the recording remaining available for one year on Coya's website under the 'Events and Presentations' section.
Company management will also be conducting one-on-one meetings with registered conference investors on February 11, 2025.
Coya Therapeutics (NASDAQ: COYA) has announced the expansion of its pipeline with COYA 303, a combination therapy of COYA 301 and GLP-1 receptor agonist for treating inflammatory diseases. COYA 303 is designed for subcutaneous administration and has shown promising results in preclinical studies with a dual immunomodulatory mechanism of action.
The company plans to publish the preclinical study results in a peer-reviewed publication in first half of 2025. The study demonstrated an additive/synergistic anti-inflammatory effect through increased Treg function and suppressed pro-inflammatory myeloid cells. Coya has filed several patent applications for the compound and is initiating translational studies with a major academic university.
The company aims to advance COYA 303 through IND-enabling studies alongside a strategic partner, focusing on neurodegenerative and autoimmune diseases.
Coya Therapeutics (NASDAQ: COYA) reports progress in its Phase 1 study of low-dose Interleukin-2 (LD IL-2) combined with CTLA4-Ig fusion protein for Frontotemporal Dementia (FTD) treatment. The study has enrolled five out of eight planned patients at Houston Methodist Hospital. The trial aims to evaluate safety, inflammation markers, Treg cell populations, and disease progression.
The company received a $5 million grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support COYA 302 development. Results will guide the design of a planned randomized, double-blinded Phase 2 trial. Recent data presented at AD/PD 2024 showed significantly reduced Treg suppressive function in FTD patients compared to controls, supporting the immune system's role in FTD pathophysiology.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotechnology company focused on regulatory T cell function enhancement, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The event will take place from December 3-5, 2024, at the Loews Coral Gables Hotel in Florida.
CEO Arun Swaminathan and Executive Chairman Howard Berman will engage in a fireside chat on December 3 at 12:55 PM ET, moderated by Evercore ISI's Director Michael DiFiore. The executives will also be available for one-on-one meetings during the conference. The presentation will be accessible via webcast and archived for one year on Coya's website.
Coya Therapeutics (NASDAQ: COYA) has outlined its strategic plans for 2025, focusing on three key programs: ALS, FTD, and Alzheimer's disease. The company plans to submit data for its COYA 302 Phase 2 ALS trial by Q2 2025, expects topline results from FTD studies in H2 2025, and will disclose additional Alzheimer's disease data in H1 2025. The company's partnership with Dr. Reddy's Laboratories, worth up to $700 million, continues to strengthen, with an anticipated $8.4 million milestone payment upon ALS trial initiation. Coya maintains a strong cash position and is pursuing additional strategic partnerships across multiple indications.
Coya Therapeutics (NASDAQ: COYA) reported Q3 2024 financial results and corporate updates. Key highlights include positive results from a low-dose IL-2 study in Alzheimer's Disease, patent filings for COYA 301 with GLP-1 receptor agonists, and leadership changes with Arun Swaminathan becoming CEO. The company's cash position was $31.1 million as of September 30, 2024. Q3 net loss increased to $4.0 million from $3.4 million year-over-year. R&D expenses rose to $2.2 million from $1.6 million, while G&A expenses increased slightly to $2.2 million from $2.0 million.
Coya Therapeutics announces Arun Swaminathan, Ph.D., as new CEO effective November 1, 2024. Dr. Swaminathan, who previously led the company's $700 million potential licensing deal with Dr. Reddy's Laboratory, will guide Coya's growth in developing treatments for neurodegenerative diseases. The company also reported encouraging results from a Phase 2 investigator-initiated trial in Alzheimer's disease using low-dose interleukin-2 (LD IL-2). The trial showed cognitive stabilization and significant CSF biomarker improvement in the lower dose IL-2 arm, validating their Treg platform approach.
Coya Therapeutics (NASDAQ: COYA) announced positive results from a Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in Alzheimer's Disease patients. The study met its primary safety endpoints and secondary endpoints for Regulatory T cell enhancement. The trial, involving 38 participants, tested two dosing regimens: every 4 weeks (q4wks) and every 2 weeks (q2wks). The q4wks dosing showed promising results, including cognitive stabilization and improved cerebrospinal fluid biomarkers. Notably, the q4wks group demonstrated a 4.93-point improvement in ADAS-Cog14 scores compared to placebo, and significant improvements in CSF Aβ42 levels. The treatment was well-tolerated with no serious adverse events reported.